[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371412-105":3,"doc-detail-371412-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ultrasensitive-detection-and-monitoring-of-circulating-tumor-dna-using-structural-variants-in-early-stage-breast-cancer","Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer","","Detection of circulating tumor DNA (ctDNA) after curative-intent therapy in early-stage breast cancer is a strong prognostic marker for recurrence. Existing assays mainly target single-nucleotide variants, with tradeoffs in sensitivity and specificity. Structural variants (SV) occur broadly across cancers and may support sensitive ctDNA detection without reducing specificity. This retrospective study evaluated a tumor-informed SV-based ctDNA assay in 100 patients, analyzing ctDNA dynamics and lead times to postoperative distant recurrence.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ultrasensitive-detection-and-monitoring-of-circulating-tumor-dna-using-structural-variants-in-early-stage-breast-cancer/371412/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ultrasensitive-detection-and-monitoring-of-circulating-tumor-dna-using-structural-variants-in-early-stage-breast-cancer/371412.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address about ctDNA testing in early-stage breast cancer?","Question",{"text":63,"@type":64},"ctDNA after curative-intent therapy predicts recurrence, but current assays mainly target single-nucleotide variants and vary in sensitivity and specificity. The study explores whether structural variants can provide comparable or better performance without compromising specificity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the ctDNA assay evaluated in this retrospective analysis?",{"text":68,"@type":64},"A tumor-informed SV-based ctDNA assay was analyzed in early-stage breast cancer patients (n=100) with many timepoints, focusing on ctDNA dynamics and how early detection related to postoperative distant recurrence.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about detection timing relative to distant recurrence?",{"text":72,"@type":64},"ctDNA was detected in most participants at baseline and appeared prior to distant recurrence in all cases. The study reports a median lead time of 417 days, supporting the clinical relevance of SV-based ultrasensitive monitoring.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371412,1790215768,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2",8,"Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer  \nMitchell J. Elliott1, Karen Howarth2, Sasha Main3, Jess Fuentes Antrs4, Philippe Echelard5, Aaron Dou1, Eitan Amir1, Michelle B. Nadler1, Elizabeth Shah6, Celeste Yu6, Scott Bratman7, Taylor Bird1, June Roh1, Elza [C. de](C. de) Bruin8, Christopher Rushton2, Yilun Chen2, Sergii Gladchuk2, Anthony M. George2, Sofia Birkelv2, Miguel Alcaide2, Lucia Oton2, Girish Putcha2,  \nSamuel Woodhouse2, Philippe L. Bedard1, Lillian L. Siu1, Hal K. Berman9, and David W. Cescon1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: The detection of circulating tumor DNA (ctDNA) after curative-intent therapy in early-stage breast cancer is highly prognostic of disease recurrence. Current ctDNA assays, mainly targeting single-nucleotide variants, vary in sensitivity and specificity. Although increasing the number of single-nucleotide variants in tumor-informed assays improves sensitivity, structural variants (SV) may achieve similar or better sensitivity without compromising specificity. SVs occur across all cancers, linked to genomic instability and tumorigenesis, with unique tumorand patient-specific breakpoints occurring throughout the genome. SVs in breast cancer are underexplored, and their potential for ctDNA detection and monitoring has not been fully evaluated.\u003Cbr>Experimental Design: We retrospectively analyzed a tumorinformed SV-based ctDNA assay in a cohort of patients with early-stage breast cancer (n ¼ 100, 568 timepoints) receiving\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | neoadjuvant systemic therapy, evaluating ctDNA dynamics and lead times to clinical recurrence in the postoperative period.\u003Cbr>Results: ctDNA was detected in 96%(91/95) of participants at baseline with a median variant allele frequency of 0.15%(range: 0. 0011%–38 . 7%); of these, 10%(9/91) had a variant allele frequency \u003C0.01% . ctDNA detection at cycle 2 (C2) of neoadjuvant therapy was associated with a higher likelihood of distant recurrence (log-rank P ¼ 0.047) and enhanced residual cancer burden prognostication (log-rank P ¼ 0.041) . ctDNA was detected prior to distant recurrence in all cases (100% sensitivity) with a median lead time of 417 days (range: 4–1,931 days) .\u003Cbr>Conclusions: These results demonstrate the clinical validity of ultrasensitive ctDNA detection and monitoring using SVs. Prospective trials are required to evaluate ctDNA-guided treatment strategies. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nThe detection of circulating tumor DNA (ctDNA) after curativeintent therapy in early-stage breast cancer (EBC) is strongly associated with disease recurrence (1–7) . First-generation tumorinformed ctDNA assays targeting multiple tumor-specific singlenucleotide variants (SNV) by multiplex PCR or next-generation sequencing (NGS) have demonstrated anal","cbCaieTYiEfG8S3G","https://ap.wps.com/l/cbCaieTYiEfG8S3G","pdf",8614682,13,"English","# Purpose\n# Experimental Design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What problem does the study address about ctDNA testing in early-stage breast cancer?\",\"answer\":\"ctDNA after curative-intent therapy predicts recurrence, but current assays mainly target single-nucleotide variants and vary in sensitivity and specificity. The study explores whether structural variants can provide comparable or better performance without compromising specificity.\"},{\"question\":\"How was the ctDNA assay evaluated in this retrospective analysis?\",\"answer\":\"A tumor-informed SV-based ctDNA assay was analyzed in early-stage breast cancer patients (n=100) with many timepoints, focusing on ctDNA dynamics and how early detection related to postoperative distant recurrence.\"},{\"question\":\"What did the results show about detection timing relative to distant recurrence?\",\"answer\":\"ctDNA was detected in most participants at baseline and appeared prior to distant recurrence in all cases. The study reports a median lead time of 417 days, supporting the clinical relevance of SV-based ultrasensitive monitoring.\"}]","Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer | PDF",1790192011,33,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46c1b1a99a2d4a37728039650afce817.webp",983,1315,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16aeb2d98976968849ba5591e24f79eb.webp",982,1314,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/251b1d3342848086449fab60b35bbabd.webp",981,1312,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bc8743c12c0c285d5866eb38a0a1beb.webp",980,1311,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,153,156,160],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":150,"show_sort_weight":151,"slug":152},9,"Religion & Spirituality",20,"religion-spirituality",{"id":151,"doc_module":4,"doc_module_name":25,"category_name":154,"show_sort_weight":151,"slug":155},"World Cup","world-cup",{"id":157,"doc_module":4,"doc_module_name":25,"category_name":158,"show_sort_weight":157,"slug":159},10,"Lifestyle","lifestyle",{"id":161,"doc_module":4,"doc_module_name":25,"category_name":162,"show_sort_weight":131,"slug":163},19,"General","general"]